References
- Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877–883.
- Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352:225–237.
- Al-Khatib SM, Stevenson WG, Ackerman MJ, et al. 2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2018;72(14):e91–e220.
- Kober L, Thune JJ, Nielsen JC, et al. Defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375:1221–1230.
- Hohnloser SH, Kuck KH, Dorian P, et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med. 2004;351:2481–2488.
- Colquitt JL, Mendes D, Clegg AJ, et al. Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technol Assess. 2014;18:1–560.
- Younis A, Goldberger JJ, Kutyifa V, et al. Predicted benefit of an implantable cardioverter-defibrillator: the madit-icd benefit score. Eur Heart J. 2021;42:1676–1684.
- Li X, Fan X, Li S, et al. A novel risk stratification score for sudden cardiac death prediction in middle-aged, nonischemic dilated cardiomyopathy patients: the estimated score. Can J Cardiol. 2020;36:1121–1129.
- Kadish A, Dyer A, Daubert JP, et al. Prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350:2151–2158.
- McMurray JJ. The icd in heart failure - time for a rethink? N Engl J Med. 2016;375:1283–1284.
- Zhang S, Singh B, Rodriguez DA, et al. Improve the prevention of sudden cardiac arrest in emerging countries: the improve sca clinical study design. Europace. 2015;1:17.
- Bilchick KC, Wang Y, Cheng A, et al. Seattle heart failure and proportional risk models predict benefit from implantable cardioverter-defibrillators. J Am Coll Cardiol. 2017;69:2606–2618.
- Shadman R, Poole JE, Dardas TF, et al. A novel method to predict the proportional risk of sudden cardiac death in heart failure: derivation of the Seattle proportional risk model. Heart Rhythm. 2015;12:2069–2077.
- Barsheshet A, Moss AJ, Huang DT, et al. Applicability of a risk score for prediction of the long-term (8-year) benefit of the implantable cardioverter-defibrillator. J Am Coll Cardiol. 2012;59:2075–2079.
- Zhang S, Ching CK, Huang D, et al. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: improve sca clinical trial. Heart Rhythm. 2020;17:468–475.